Universal Prophylaxis with Oral Valganciclovir Significantly Reduces First Year CMV Disease in Kidney Transplant Recipients

被引：0
|
作者：
Wu, M. -J. [1 ]
Tu, P. -T. [1 ]
机构：
[1] Taichung Vet Gen Hosp, Dept Med, Div Nephrol, Taichung, Taiwan
来源：
TRANSPLANTATION | 2012年 / 94卷 / 10期
关键词：
D O I：
10.1097/00007890-201211271-01023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
399
引用
收藏
页码：531 / 531
页数：1
相关论文
共 50 条
  • [1] Universal Valganciclovir Prophylaxis Significantly Reduces Episodes of First-Year Cytomegalovirus Disease and Biopsy-Proven Acute Rejection in Kidney Transplant Recipients
    Tu, P. T.
    Shu, K. H.
    Cheng, C. H.
    Chen, C. H.
    Yu, T. M.
    Chuang, Y. W.
    Huang, S. T.
    Tsai, S. F.
    Cheng, C. Y.
    Wu, M. J.
    [J]. TRANSPLANTATION PROCEEDINGS, 2014, 46 (02) : 574 - 577
  • [2] Oral valganciclovir prophylaxis in kidney transplant recipients
    Manuel, O.
    Fellay, J.
    Venetz, J-P.
    Sturzenegger, N.
    Meylan, R.
    Pascual, M.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S16 - S16
  • [3] Valganciclovir for CMV prophylaxis in paediatric transplant recipients.
    Wiesmayr, S
    Stelzmueller, I
    Jungraithmayr, T
    Mark, W
    Larcher, C
    Margreiter, R
    Zimmerhackl, L
    Bonatti, H
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 355 - 355
  • [4] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    [J]. PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [5] Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation
    Klem, P.
    Al-Omar, L.
    Cooper, J.
    Davis, S.
    Gralla, J.
    Choe, D.
    Wiseman, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 468 - 468
  • [6] Valganciclovir prophylaxis for 6 months prevents CMV-induced disease in 96% of kidney transplant recipients
    Cantarovich, Diego
    Giral, Magali
    Dantal, Jacques
    Blacho, Gilles
    Soulillou, Jean-Paul
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 90 - 91
  • [7] Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis
    Belfield, K.
    Cohen, E.
    Malinis, M.
    Baghban, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 514 - 514
  • [8] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad
    [J]. TRANSPLANT INTERNATIONAL, 2019, 32 : 295 - 295
  • [9] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad Tassaduq
    [J]. SWISS MEDICAL WEEKLY, 2019, : 19S - 19S
  • [10] The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation
    Villeneuve, Claire
    Rerolle, Jean-Phillipe
    Couzi, Lionel
    Westeel, Pierre-Francois
    Etienne, Isabelle
    Esposito, Laure
    Kamar, Nassim
    Buchler, Mathias
    Thierry, Antoine
    Marquet, Pierre
    Monchaud, Caroline
    [J]. TRANSPLANTATION DIRECT, 2024, 10 (08):
12345